Is OMER or ORKA more undervalued in 2026?

CirclFi compares Omeros Corporation (OMER) and Oruka Therapeutics, Inc. (ORKA) using 13 institutional-grade valuation models. OMER has a Quality of Company score of 3.3/10 while ORKA scores 4.3/10.

Which is a better buy — OMER or ORKA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OMER and ORKA valuations compare?

OMER at $11.15 and ORKA at $57.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OMER vs ORKA Valuation Comparison 2026 — Intrinsic Value Analysis

OMER

Biotechnology

Omeros Corporation

Quality

3.3

out of 10

Value Trap

LOW

Price

$11.15

Last close

Models

10/13

Active

ORKA

Biotechnology

Oruka Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$57.98

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	OMER Fair Value	OMER Upside	ORKA Fair Value	ORKA Upside
Bayesian DCF	Intrinsic	$2.45	-78.0%	$17.90	-69.1%
Earnings Power Value	Intrinsic	—	—	$31.09	-55.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.03	-72.8%	$5.63	-90.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OMER vs ORKA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OMER vs ORKA — Which Stock Is More Undervalued?

ORKA scores higher with a 4.3/10 quality rating vs OMER's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Omeros Corporation (OMER) and Oruka Therapeutics, Inc. (ORKA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OMER currently trades at $11.15 with a QOC of 3.3/10, while ORKA trades at $57.98 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).